Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences
03 Setembro 2020 - 8:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced
that the Company will present at two upcoming virtual investor
conferences.
Wells Fargo 2020 Virtual Healthcare
ConferenceDate: Thursday, September 10Time: 2:00 PM
Eastern Time
Oppenheimer Fall Healthcare Life
Sciences & MedTech SummitDate: Tuesday, September
21Time: 4:10 PM Eastern Time
Live webcasts of the events will be available on
the Sunesis website at http://ir.sunesis.com. A replay of each will
be archived on the "Calendar of Events" page in the Investors and
Media section of the Sunesis website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing novel targeted inhibitors for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, including first-in-class PDK1 inhibitor
SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib is
completing a Phase 1b trial in patients with advanced B cell
malignancies.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media Inquiries: |
|
Par Hyare |
Maeve Conneighton |
|
Sunesis Pharmaceuticals Inc. |
Argot Partners |
|
650-266-3784 |
212-600-1902 |
|
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Sunesis Pharmaceuticals Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de